Samsung BioLogics in Talks for 15 Contracts Amid Pharma Boom
- Samsung BioLogics is contract manufacturer for drug industry
- Biologics unit began trading last year after Korean IPO
This article is for subscribers only.
Samsung BioLogics Co., an arm of South Korea’s biggest conglomerate, said it is in negotiations to manufacture drugs for more than 15 international pharmaceutical companies as it tries to expand in the growing industry for complex biologic medicines.
The talks mostly involve U.S. and European firms, Chief Executive Officer Kim Tae-han said in an April 19 interview at the company’s headquarters in Incheon. Winning any of those contracts would be a boost for the drug manufacturer, which started trading last year and currently has agreements with about six clients -- including Switzerland’s Roche Holding AG and U.S.-based Bristol-Myers Squibb Co. -- for nine different products.